用于心力衰竭的心脏趋向性腺相关病毒基因治疗:一项1期试验
本研究为1期试验,评估单次顺行冠状动脉输注AB-1002在非缺血性心肌病、纽约心脏协会III级心力衰竭且左心室射血分数15-35%患者中的安全性和可行性。患者接受3.25×10^13(队列1,n=6)或1.08×10^14(队列2,n=5)病毒基因组。研究者未将不良事件或严重不良事件归因于研究治疗,大多数不良事件为轻或中度;发生1例死亡,被认为与AB-1002治疗无关。初步疗效评估显示两队列纽约心脏协会分级和左心室射血分数改善,队列1峰值耗氧量和6分钟步行试验表现改善。结果支持AB-1002在临床试验中进一步评估。
要点
- AB-1002单次顺行冠状动脉输注在非缺血性心肌病、NYHA III级、LVEF 15-35%患者中可行。
- 研究者未将不良事件或严重不良事件归因于AB-1002;大多数不良事件为轻或中度。
- 发生1例死亡,认为与AB-1002治疗无关;出现自限性、轻度、无症状的肝酶升高,主要见于队列2。
核心结论
- 结果支持AB-1002在临床试验中进一步评估。
研究设计与样本
- 1期研究,评估单次顺行冠状动脉输注AB-1002在非缺血性心肌病、纽约心脏协会III级心力衰竭且左心室射血分数15-35%患者中的安全性和可行性。
- 患者接受3.25×10^13病毒基因组(队列1,n=6)或1.08×10^14病毒基因组(队列2,n=5)。
- 研究共纳入9名男性和2名女性。
主要发现
- 研究者未将不良事件或严重不良事件归因于研究治疗;大多数不良事件为轻或中度。
- 发生1例死亡,认为与AB-1002治疗无关。
- 出现自限性、轻度、无症状的肝酶升高,主要见于队列2。
- 初步疗效评估显示两队列纽约心脏协会分级和左心室射血分数改善,队列1峰值耗氧量和6分钟步行试验表现改善。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Innovative approaches for the treatment of heart failure are needed beyond conventional medical therapy to reverse ventricular dysfunction and modify the course of the disease. AB-1002, a chimeric cardiotropic adeno-associated viral vector that delivers constitutively active protein phosphatase 1 inhibitor 1 to cardiomyocytes, improves cardiac function in preclinical models of heart failure. Here we carried out a phase 1 study to evaluate the safety and feasibility of a single antegrade coronary artery infusion of AB-1002 in patients with nonischemic cardiomyopathy, New York Heart Association class III heart failure, and a left ventricular ejection fraction of 15-35%. Patients received 3.25 × 1013 viral genomes (cohort 1, n = 6) or 1.08 × 1014 viral genomes (cohort 2, n = 5). In total, nine men and two women were included in the study. No adverse events (AEs) or serious AEs were attributed by the investigators to the study treatment; most AEs were mild or moderate in severity. One death occurred, which was considered not to be related to the treatment with AB-1002. Self-limiting, mild, asymptomatic elevations in liver enzymes occurred, predominantly in cohort 2. The preliminary assessments of efficacy outcomes showed improvements in the New York Heart Association class and left ventricular ejection fraction in both cohorts and improvements in peak oxygen consumption and 6-min walk test performance in cohort 1. These results support the further assessment of AB-1002 in clinical trials. The ClinicalTrials.gov registration was NCT04179643 .
引用
- Henry TD, Chung ES, Alvisi M, et al. Cardiotropic AAV gene therapy for heart failure: a phase 1 trial. Nat Med. 2025. PMID: 41120766. doi:10.1038/s41591-025-04011-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。